Jalalon, Wilma A.

HRN: 27-82-57  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
09/21/2025
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
09/21/2025
09/28/2025
IV
500
Q8
Liver Cirrhosis
Waiting Final Action 
09/24/2025
RIFAXIMIN 200MG (TAB)
09/24/2025
10/01/2025
PO
200mg
Q12
AGE
Checking Initial Appropriateness 
09/24/2025
RIFAXIMIN 200MG (TAB)
09/24/2025
10/01/2025
PO
200mg
Q8
AGE
Checking Initial Appropriateness 
09/24/2025
RIFAXIMIN 200MG (TAB)
09/24/2025
10/01/2025
PO
400mg
TID
AGE
Checking Initial Appropriateness 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: